Skip to content

Study · Randomized controlled trial · 2000

2 results

Is endometrial pre-treatment of value in improving the outcome of transcervical resection of the endometrium?

Rai VS, Gillmer MD, Gray W

Human reproduction (Oxford, England)1 Sept 2000Cited by 21 (Europe PMC)

PMID10967001 (opens in a new tab)DOI10.1093/humrep/15.9.1989 (opens in a new tab)PepBankPUB-10967001
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    Nafarelin pre-treatment reduced median endometrial thickness versus no pre-treatment before endometrial resection.

    In plain wordsNafarelin reduced endometrial thickness compared with no pre-treatment.

    Peptide
    Nafarelin
    Outcome
    DecreaseMedian endometrial thickness
    Study

    n: not reported in source

    Comparator
    No pre-treatment
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Danazol and nafarelin produced significantly lower median endometrial thickness than no pre-treatment.
    1 context sentence
    Summary · context
    A prospective randomized trial comparing three endometrial pre-treatment agents (danazol, medroxyprogesterone acetate or nafarelin) with no pre-treatment was conducted.
  2. 02HumanRandomized controlled trialEfficacy outcome

    Nafarelin pre-treatment did not significantly change amenorrhoea rates versus no pre-treatment.

    In plain wordsAmenorrhoea rates did not differ significantly between nafarelin and no pre-treatment.

    Peptide
    Nafarelin
    Outcome
    No significant changeAmenorrhoea rate
    Study

    n: not reported in source

    Comparator
    No pre-treatment
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There were, however, no significant differences in the rates of amenorrhoea in any of the pre-treatment groups compared with that in the control group.
    1 context sentence
    Summary · context
    A prospective randomized trial comparing three endometrial pre-treatment agents (danazol, medroxyprogesterone acetate or nafarelin) with no pre-treatment was conducted.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.